Opinion|Videos|December 2, 2024
Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management
Author(s)Michael Levy, MD, PhD
Key Takeaways
- Rituximab shows higher hospitalization rates than complement inhibitors, influencing treatment decisions in NMOSD management.
- B-cell depletion by rituximab may not fully prevent relapses, affecting its efficacy in NMOSD.
A panelist discusses how comparing hospitalization rates, relapse risks, and safety considerations between rituximab and other NMOSD therapies, such as complement inhibitors, can provide valuable insights to guide treatment decisions, manage healthcare costs, and optimize patient quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do hospitalization rates for rituximab compare with those seen in patients treated with complement inhibitors or other therapies?
- What implications will this have on treatment decisions?
- Please review any underlying biological or mechanistic associated with higher relapse rates reported with rituximab.
- What are some key safety considerations beyond relapse rates that may need to be addressed with long-term rituximab use in patients with NMOSD?
- What implications do relapse rates and hospitalization trends have on healthcare costs and patient quality of life in NMOSD management?
Advertisement
Related to this article
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
2
Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
3
Recapping the 2026 STARS Conference and the Push for Interdisciplinary Stuttering Care: Gerald Maguire, MD
4
NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease
5